Reaching IND is a major milestone. But, the journey is complex, resource-intensive and risky. 

Each step of the process generates a sizeable amount of data, which then needs to be collated and interpreted. Although some of these steps are carried out in parallel, many rely on the results of previous stages to ensure an optimal outcome. We understand that each molecule is unique, so flexibility is crucial when shaping your program. 

To discover how to maximize the value of early phase material and match your development path to your IND milestones. 


  • Dr. Raymond Donninger, Senior Director Commercial Development, Early Development Services, Lonza Biologics 


By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content

Latest briefing from the Knowledge Center